Forget Weight Loss Drugs: Here's Another Reason to Buy Eli Lilly Stock

Eli Lilly is acquiring AtaiBeckley for $2.8 billion, marking the drugmaker's 12th acquisition this year and pushing its strategy beyond the blockbuster weight loss franchise into mental health. The deal centers on psychedelic-based therapies for treatment-resistant depression, a segment the company sees as complementary despite generating smaller revenues than its GLP-1 portfolio.

The acquisition signals Eli Lilly's intent to diversify revenue streams as competition intensifies in the weight loss drug market. AtaiBeckley brings a pipeline focused on psychedelic compounds targeting depression cases that have failed conventional treatments, adding a clinical-stage foothold in a sector drawing increased pharmaceutical interest.

Eli Lilly has deployed capital aggressively in 2024, with this transaction representing the largest of its dozen deals. The mental health expansion offers a hedge against pricing pressure and patent cliffs in its core obesity and diabetes franchises, though the market opportunity remains materially smaller than the multi-billion-dollar GLP-1 category that has driven recent share price gains.